De Novo device
Essilor® Stellest®
Essilor Of America, Inc. · Prescription Spectacle Lenses To Reduce The Progression Of Myopia (QUR, Class II) · First FDA decision Sep 25, 2025, newest Sep 25, 2025Nearsightedness and refractive error
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
10
Naming "Essilor Stellest"
MAUDE reports
0
Brand "Essilor Stellest", since 2015
PubMed studies
4
Mentioning "Essilor Stellest"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Essilor® Stellest®New device typeBreakthroughDe Novo
DEN250016 · Decided Sep 25, 2025 · 150 days after receipt
Device type: Prescription Spectacle Lenses To Reduce The Progression Of Myopia (QUR) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Essilor Stellest", any status and sponsor, newest update first.
Shanghai Eye Disease Prevention and Treatment CenterAcademic, hospital or other
NCT07120737 · 0 participants · Start Oct 30, 2026 · Primary completion Oct 30, 2026
Device: H.A.L.T. MAX spectacles · For: Myopia; High Myopia
Sites: Shanghai, China
Essilor InternationalNot on our public-company list
NCT07440134 · 100 participants (planned) · Start Apr 3, 2026 · Primary completion May 2027
Device: Ophtalmic measurements · For: Teenagers; Myopia
Sites: Paris, France
- Efficacy of Myopia-control Lenses in a Population of Young Adults : the OPTIMA StudyPivotal-lookingNot yet recruiting
Fondation Ophtalmologique Adolphe de RothschildResearch network
NCT07804043 · 134 participants (planned) · Start Nov 1, 2026 · Primary completion Dec 1, 2028
Device: Essilor® Stellest® 2.0 myopia-slowing lenses; Standard lenses · For: Myopia
Sites: Paris, France
- Essilor® Stellest® Lenses Multicentre European Study (SLOMES)Active, not recruiting
Essilor InternationalNot on our public-company list
NCT06263946 · 150 participants (planned) · Start Mar 22, 2024 · Primary completion May 4, 2027
Device: Essilor® Stellest® spectacle lenses · For: Myopia
Sites: Paris, France; Dublin, Ireland; Rotterdam, Netherlands
University of FaisalabadAcademic, hospital or other
NCT07645183 · 90 participants · Start Jul 1, 2025 · Primary completion May 30, 2026
Device: Lenslet Spectacles; Violet Excitation Filter Glasses and 1 more · For: Myopia (Disorder); Refraction Error
Sites: Faisalābad, Pakistan
- Efficacy of Multi-Type Photolithography Flat Microstructure Lenses for Childhood Myopia ControlPivotal-lookingNot yet recruiting
Shanghai Eye Disease Prevention and Treatment CenterAcademic, hospital or other
NCT07535658 · 255 participants (planned) · Start Apr 15, 2026 · Primary completion Sep 30, 2027
Device: wearing photolithography plano microstructure lenses with multi-point defocus design, non-fading optical property; wearing Plano microstructure lenses featuring multi-point defocus design with aspherical lenslets (Essilor Stellest) and 3 more · For: Myopia
Sites: Shanghai, China
- Stellest Lens Wear in Adult Progressing MyopesActive, not recruiting
University of UlsterAcademic, hospital or other
NCT06520124 · 42 participants (planned) · Start Oct 17, 2024 · Primary completion Dec 30, 2027
Device: Essilor® Stellest® spectacle lens; Single-vision spectacle lens · For: Myopia, Progressive
Sites: Coleraine, United Kingdom
- Myopia Control With a Innovative Spectacle LensPivotal-lookingCompleted
Essilor InternationalNot on our public-company list
NCT05174780 · 159 participants · Start Dec 29, 2021 · Primary completion Oct 20, 2025
Device: innovative myopia control spectacle lens; Single vision spectacle lens · For: Myopia
Sites: San Diego, California; Longwood, Florida; Chicago, Illinois · 9 sites in all
- Highly Aspherical Lenslet (HAL) and Binocular Vision (BV) Disorders [HALT X(T) Study]Not yet recruiting
Singapore National Eye CentreGovernment (non-federal)
NCT06863675 · 40 participants (planned) · Start Jun 1, 2025 · Primary completion Jun 30, 2028
Device: HAL lenses for children with strabismus; SVL for children with strabismus · For: Myopia; Strabismus
Sites: Singapore, Singapore
- Slow Myopia Progression With Different Irradiance LightStatus unknown
Beijing Airdoc Technology Co., Ltd.Not on our public-company list
NCT05881655 · 75 participants (planned) · Start May 20, 2023 · Primary completion May 30, 2024
Device: Airdoc Red Lighting Device; Special Spectacles to Control Myopia · For: Myopia, Progressive
Sites: Shanghai, China
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Essilor Stellest", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QUR
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Essilor Stellest"[tiab]. The summary above synthesizes these.
- Multiple segment spectacle lenses for myopia control. Part 1: Optics.
Radhakrishnan H, Lam CSY, Charman WN · Ophthalmic Physiol Opt · 2023Research Support, Non-U.S. Gov't
- Additive Effect of Highly Aspherical Lenslet Target Spectacles to Children Inadequately Controlled by Atropine Monotherapy.
Sim BX, Loh KL, Htoon HM, et al. · Ophthalmol Sci · 2025
- Comparison of the performance of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) and highly aspherical lenslets (HAL) spectacles.
Lembo A, Schiavetti I, Serafino M, et al. · BMJ Paediatr Open · 2024Comparative Study
- Google Trends Analysis of Interest in Pediatric Myopia-Control Spectacle Lenses Following FDA Authorization of Essilor Stellest.
Gill AS, Tseng CC, Burke PS, et al. · Cureus · 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.